Vision, Integrity, Expertise
Soligenix, Inc. is a late stage biopharmaceutical company committed to developing products that address unmet medical needs in the areas of inflammation, oncology and biodefense. Soligenix has two areas of focus: 1) a therapeutics segment dedicated to the development of products for orphan diseases and areas of unmet medical need such as cutaneous T-cell lymphoma, oral mucositis, pediatric Crohn's disease, acute radiation enteritis, and 2) a vaccines/biodefense segment to develop vaccines and therapeutics for military and civilian applications in the areas of ricin exposure, anthrax exposure, gastrointestinal acute radiation syndrome, and melioidosis.
Tuesday, June 23, 2015Soligenix Announces Collaboration with the National Organization for Rare Disorders and the Cutaneous Lymphoma Foundation in Advancing its Phase 3 Study of SGX301 for the Treatment of Cutaneous T-Cell Lymphoma
Tuesday, June 02, 2015Soligenix Announces Publication of Successful Application of its Heat Stabilization Technology to a Human Papillomavirus Vaccine
Thursday, May 28, 2015Soligenix Announces Collaboration with the University of Hawai’i at Manoa and Hawaii Biotech to Develop Heat Stable Ebola Vaccine
Friday, July 17, 2015 - International Innovation - Bullseye: Targeting Cancer with Selective Innovations, Issue 190 (pdf)
Partnering with Us
Soligenix is interested in identifying new partnership and merger opportunities for its existing products as well as new in-licensing candidates in the areas of HSC transplant, supportive cancer care, gastrointestinal and biodefense.